BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 15476062)

  • 1. Hyperphosphorylated tau protein in the cerebrospinal fluid of patients with Alzheimer's disease and other dementias: preliminary findings.
    Hartmann AP; Almeida SM; Livramento JA; Nitrini R; Takahashi D; Caramelli P
    Arq Neuropsiquiatr; 2004 Sep; 62(3B):751-5. PubMed ID: 15476062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231.
    Buerger K; Zinkowski R; Teipel SJ; Tapiola T; Arai H; Blennow K; Andreasen N; Hofmann-Kiefer K; DeBernardis J; Kerkman D; McCulloch C; Kohnken R; Padberg F; Pirttilä T; Schapiro MB; Rapoport SI; Möller HJ; Davies P; Hampel H
    Arch Neurol; 2002 Aug; 59(8):1267-72. PubMed ID: 12164722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical indications for analysis of Alzheimer's disease CSF biomarkers.
    Engelborghs S
    Rev Neurol (Paris); 2013 Oct; 169(10):709-14. PubMed ID: 24016466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of a prototype tau Thr231 phosphorylation CSF ELISA as a potential biomarker for Alzheimer's disease.
    Santos JRF; Bauer C; Schuchhardt J; Wedekind D; Waniek K; Lachmann I; Wiltfang J; Vogelgsang J
    J Neural Transm (Vienna); 2019 Mar; 126(3):339-348. PubMed ID: 30767082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P).
    Koopman K; Le Bastard N; Martin JJ; Nagels G; De Deyn PP; Engelborghs S
    Neurochem Int; 2009 Sep; 55(4):214-8. PubMed ID: 19524111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias.
    de Souza LC; Lamari F; Belliard S; Jardel C; Houillier C; De Paz R; Dubois B; Sarazin M
    J Neurol Neurosurg Psychiatry; 2011 Mar; 82(3):240-6. PubMed ID: 20802215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.
    Hampel H; Buerger K; Zinkowski R; Teipel SJ; Goernitz A; Andreasen N; Sjoegren M; DeBernardis J; Kerkman D; Ishiguro K; Ohno H; Vanmechelen E; Vanderstichele H; McCulloch C; Moller HJ; Davies P; Blennow K
    Arch Gen Psychiatry; 2004 Jan; 61(1):95-102. PubMed ID: 14706948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.
    Sunderland T; Linker G; Mirza N; Putnam KT; Friedman DL; Kimmel LH; Bergeson J; Manetti GJ; Zimmermann M; Tang B; Bartko JJ; Cohen RM
    JAMA; 2003 Apr 23-30; 289(16):2094-103. PubMed ID: 12709467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic Accuracy of Cerebrospinal Fluid Amyloid-β Isoforms for Early and Differential Dementia Diagnosis.
    Struyfs H; Van Broeck B; Timmers M; Fransen E; Sleegers K; Van Broeckhoven C; De Deyn PP; Streffer JR; Mercken M; Engelborghs S
    J Alzheimers Dis; 2015; 45(3):813-22. PubMed ID: 25633670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid levels of a 20-22 kDa NH2 fragment of human tau provide a novel neuronal injury biomarker in Alzheimer's disease and other dementias.
    Amadoro G; Corsetti V; Sancesario GM; Lubrano A; Melchiorri G; Bernardini S; Calissano P; Sancesario G
    J Alzheimers Dis; 2014; 42(1):211-26. PubMed ID: 24851856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment.
    Parnetti L; Chiasserini D; Eusebi P; Giannandrea D; Bellomo G; De Carlo C; Padiglioni C; Mastrocola S; Lisetti V; Calabresi P
    J Alzheimers Dis; 2012; 29(1):229-38. PubMed ID: 22232006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia.
    Skillbäck T; Farahmand BY; Rosén C; Mattsson N; Nägga K; Kilander L; Religa D; Wimo A; Winblad B; Schott JM; Blennow K; Eriksdotter M; Zetterberg H
    Brain; 2015 Sep; 138(Pt 9):2716-31. PubMed ID: 26133663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of rCBF (SPECT), CSF tau, and cognitive function in patients with dementia of the Alzheimer's type, other types of dementia, and control subjects.
    Tsolaki M; Sakka V; Gerasimou G; Dimacopoulos N; Chatzizisi O; Fountoulakis KN; Kyriazis G; Papanastasiou J; Kazis A
    Am J Alzheimers Dis Other Demen; 2001; 16(1):21-31. PubMed ID: 11416945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased cerebrospinal fluid levels of double-stranded RNA-dependant protein kinase in Alzheimer's disease.
    Mouton-Liger F; Paquet C; Dumurgier J; Lapalus P; Gray F; Laplanche JL; Hugon J;
    Biol Psychiatry; 2012 May; 71(9):829-35. PubMed ID: 22281122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkers.
    Sjögren M; Andreasen N; Blennow K
    Clin Chim Acta; 2003 Jun; 332(1-2):1-10. PubMed ID: 12763273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF.
    Kahle PJ; Jakowec M; Teipel SJ; Hampel H; Petzinger GM; Di Monte DA; Silverberg GD; Möller HJ; Yesavage JA; Tinklenberg JR; Shooter EM; Murphy GM
    Neurology; 2000 Apr; 54(7):1498-504. PubMed ID: 10751266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study.
    Andreasen N; Vanmechelen E; Van de Voorde A; Davidsson P; Hesse C; Tarvonen S; Räihä I; Sourander L; Winblad B; Blennow K
    J Neurol Neurosurg Psychiatry; 1998 Mar; 64(3):298-305. PubMed ID: 9527138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.